| 000 | 01502 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250511160153.0 | ||
| 264 | 0 | _c19760902 | |
| 008 | 197609s 0 0 eng d | ||
| 022 | _a0362-1642 | ||
| 024 | 7 |
_a10.1146/annurev.pa.16.040176.000413 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAzarnoff, D L | |
| 245 | 0 | 0 |
_aTherapeutic implications of bioavailability. _h[electronic resource] |
| 260 |
_bAnnual review of pharmacology and toxicology _c1976 |
||
| 300 |
_a53-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdministration, Topical |
| 650 | 0 | 4 |
_aAnalgesics _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xmetabolism |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xmetabolism |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xmetabolism |
| 650 | 0 | 4 |
_aAnticoagulants _xmetabolism |
| 650 | 0 | 4 |
_aAnticonvulsants _xmetabolism |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aBiopharmaceutics |
| 650 | 0 | 4 |
_aCardiac Glycosides _xmetabolism |
| 650 | 0 | 4 |
_aDiuretics _xmetabolism |
| 650 | 0 | 4 | _aDrug Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xmetabolism |
| 650 | 0 | 4 |
_aSteroids _xmetabolism |
| 650 | 0 | 4 |
_aThyroid Hormones _xmetabolism |
| 650 | 0 | 4 |
_aVitamins _xmetabolism |
| 700 | 1 | _aHuffman, D H | |
| 773 | 0 |
_tAnnual review of pharmacology and toxicology _gvol. 16 _gp. 53-66 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1146/annurev.pa.16.040176.000413 _zAvailable from publisher's website |
| 999 |
_c945550 _d945550 |
||